目的 探討達格列凈聯(lián)合二甲雙胍對2型糖尿病的臨床治療效果。方法 選取2016年1月-2017年6月西安市第一醫(yī)院收治的2型糖尿病患者97例，按治療方法分為對照組48例、觀察組49例。所有患者均給予1個月的導入治療，結束后對照組使用二甲雙胍治療，觀察組在此基礎上聯(lián)合達格列凈治療。兩組均連續(xù)治療3個月，每2周對患者進行一次電話隨訪，每1個月對患者進行一次門診隨訪。比較兩組治療前后血糖、血流動力學相關指標的變化，比較兩組治療期間不良反應的發(fā)生情況。結果 兩組治療前空腹血糖（FBG）、糖化血紅蛋白（HbA1c）、餐后2 h血糖（2hPG）間無顯著差異，治療后兩組以上指標均顯著降低（P<0.05），且觀察組顯著低于對照組（P<0.05）。兩組治療前視網(wǎng)膜中央動脈（CRA）、睫狀后動脈（PCA）的收縮期峰值流速（PSV）、舒張末期血流速度（EDV）、阻力指數(shù)（RI）間無顯著差異，治療后以上指標均顯著升高（P<0.05），且觀察組較對照組更顯著（P<0.05）。治療期間，觀察組的不良反應發(fā)生率是18.37%，與對照組的18.75%間無顯著差異。結論 達格列凈聯(lián)合二甲雙胍對2型糖尿病的療效確切，可顯著降低FBG、HbA1c、2hPG水平，改善球后動脈血流動力學相關指標，值得臨床應用推廣。

Objective To explore the clinical efficacy of dapagliflozin combined with metfotmin on type 2 diabetes mellitus. Methods Selected 97 patients with type 2 diabetes mellitus in our hospital from January 2016 to June 2017. All patients were divided into control group (n=48) and observation group (n=49). All patients were given 1 month of induction therapy, the control group were treated with metformin after the induction therapy, the observation group were treated with dapagliflozin on the basis of control group. The blood glucose, hemodynamics and the incidence of adverse reactions were compared between two groups. Results There was no significant difference between FBG, HbA1c and 2hPG before treatment in both groups. After treatment, the above two indexes were significantly lower (P<0.05), and the observation group was more obvious than the control group (P<0.05). There were no significant differences in PSV, EDV and RI between CRA and PCA before treatment in both groups, and the above indexes were significantly increased after treatment (P<0.05), and the observation group was more significant than the control group (P<0.05). During the treatment, The incidence of adverse reactions of the observation group (18.37%) was not significantly different from that in the control group (18.75%). Conclusions Dapagliflozin combined with metformin has definite curative effect on type 2 diabetes mellitus, which can significantly reduce the levels of FBG, HbA1c and 2hPG, and improve hemodynamics of the posterior arteries related indicators, which is worthy of promotion in clinical application.